Kanvas Biosciences raises $48.0M Series A (United States, Jun 2026)
$48.0M
$48 million Series AGenerated social card
Headline
Kanvas Biosciences raises $48 million to advance microbiome cancer therapies - Cornell Chronicle
About
Kanvas Biosciences is focused on developing microbiome-based cancer therapies, leveraging a breakthrough imaging platform to map the gut microbiome. The company aims to improve cancer immunotherapy outcomes and address malnutrition-related gut diseases, with its foundational technology emerging from research at Cornell University.
Article summary
Kanvas Biosciences raises $48 million to advance microbiome cancer therapies Cornell Chronicle
Founder
Hao Shi
Co-founder
Investors · 2
DCVCLead
FUND
Lions Capital
FUND
Related rounds
| Jul 21, 2026 | 30 Sundays | $6.7M | — | United States |
| Jul 21, 2026 | Skylark Labs | $150.0M | — | United States |
| Jul 21, 2026 | Infinity | $15.0M | — | United States |
| Jul 20, 2026 | Natural | $30.0M | Series A | United States |